⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 1, 2025

Supplementary Figure S5 from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy

Katsushige Kawase Shusuke Kawashima Tatsuya Nishi Takashi Inozume Takao Morinaga Masahito Kawazu Toyoyuki Hanazawa Yosuke Togashi

View Full Paper

Ask AI

Bookmark

Share

Key Points

Resistance to cancer immunotherapy is linked to the regulation of CD155 expression by the PI3K/Akt signaling pathway in tumors.
Data show differences in tumor-infiltrating immune cells present in EMT6 tumors treated with harmine, suggesting therapeutic implications.
Analysis focused on understanding how PI3K/Akt regulates immune response in cancer therapy resistance, highlighting potential intervention points.
These findings support further investigation into CD155 as a target for enhancing the efficacy of cancer immunotherapy.

Implication

Observational analysis reveals tumor-infiltrating immune cells in EMT6 tumors treated with harmine, indicating a key role of the PI3K/Akt pathway.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kawase et al. (2025) studied this question.

synapsesocial.com/papers/68de68f183cbc991d0a21acf https://doi.org/10.1158/2326-6066.30255049

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 3 from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy2025
2Supplementary Figure S6 from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy2025
3Supplementary Figure S2 from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy2025
4Supplementary Figure S1 from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy2025
5Supplementary Figure S4 from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy2025